Penn Study Illuminates Why Cancers Caused by BRCA Mutations Recur

November 10, 2022 11:36 am

Findings uncover possible drivers of recurrent breast and ovarian cancers among women carrying high-risk genetic mutations, pointing to methods to more effectively treat disease

PHILADELPHIA — Researchers at the University of Pennsylvania’s Basser Center for BRCA at the Abramson Cancer … Read more

Ovarian cancer surveillance results in earlier diagnosis for women with faulty BRCA genes who want to defer surgery

November 1, 2022 4:17 pm

by British Medical Journal

Regularly monitoring women with faulty BRCA genes that make them highly susceptible to ovarian cancer results in earlier stage diagnosis in those who want to defer preventive surgery, finds research published online in the Journal of Read more

Anti-cancer drugs, olaparib and adavosertib, work best when given sequentially in patients with advanced tumours driven by DNA damage response mutations: results from Phase Ib STAR clinical trial

October 27, 2022 2:26 pm

Barcelona, Spain: Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely treated with two drugs, olparib and adavosertib, if they are given in sequence rather than concurrently.

Presenting results from the … Read more

Melissa Frey, MD, on Disparities in Ovarian Cancer Genetic Testing

October 19, 2022 10:40 am

by Mark L. Fuerst

Most people with a hereditary ovarian cancer syndrome are unaware of their underlying mutation, and the majority have not had genetic testing.

In a recent article in the ASCO Educational Book, Melissa Frey, MD, MS, … Read more

Identifying the Underlying Causes of Ovarian Cancer

October 6, 2022 1:48 pm

by Cedars-Sinai

New Studies Led by Cedars-Sinai Investigators Help Pinpoint Genetic Risk Factors Tied to Increased Risk of Ovarian Cancer and Suggest How to Better Identify Women Most At Risk

Image on left: Simon Gayther, PhD, professor of Biomedical Sciences, Read more

Maintenance Therapy the ‘Biggest Breakthrough in Decades’ for Ovarian Cancer

September 15, 2022 1:54 pm

by Karen Blum

Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.

Karen Hanna was first diagnosed with ovarian cancer in April 2013. At the time,

Read more

Niraparib Maintenance Provides Durable Long-term Remission in High-Risk Advanced Ovarian Cancer

September 15, 2022 10:45 am

by Kristi Rosa

Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.

Maintenance treatment with niraparib (Zejula) produced a sustained and

Read more

Maintenance PARP Inhibition Boosts OS in Two Ovarian Cancer Trials

September 9, 2022 10:37 am

by Mike Bassett

— Results from SOLO-1 and PAOLA-1 show “clinically meaningful” long-term results with olaparib

PARIS — Olaparib (Lynparza) maintenance therapy appears to offer a long-term overall survival (OS) benefit for women with ovarian cancer, according to two phase … Read more

Study Finds Genetic Counseling for Breast, Ovarian Cancer Syndrome Did Not Significantly Increase with Clinician Support

August 15, 2022 11:11 am

by Erin Hunter

Women at high risk for breast and ovarian cancer felt less worried and better informed with educational intervention, even if their attendance of genetic counseling did not significantly increase.

A new study shows that access to clinician

Read more

Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response

July 7, 2022 10:30 am

NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.

For Read more

Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses

April 12, 2022 1:12 pm

by Alison Kanski

NEW YORK – An investigational AstraZeneca drug that showed activity at a range of doses across differently mutated cancers with limited toxicity exemplifies the versatility of next-generation PARP1 inhibitors, according to researchers at the American Society for … Read more

Elimusertib Shows Promise for Solid Tumors With ATM Loss and DDR Gene Defects

April 10, 2022 2:29 pm

by Ariana Pelosci

Data regarding different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects display early efficacy of the therapy.

Patients with advanced solid tumors who have ATM gene alterations

Read more

New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy

April 5, 2022 3:27 pm

by Charles Bankhead

— Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk

The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis … Read more

Key to detecting ovarian cancer early may be in the fallopian tubes

April 4, 2022 3:20 pm

by Caren Begun

Tennis legend Chris Evert—known for her 18-time grand slam success in the sport—has made recent headlines after revealing an early-stage ovarian cancer diagnosis and speaking out to help others by sharing her personal experience.

According to the … Read more

BRCA Testing Underused in Women With Ovarian Cancer

January 14, 2022 9:00 am

by M. Alexander Otto, MMS, PA

Despite unequivocal recommendations for universal germline BRCA testing in women with ovarian cancer, an analysis of a large commercial insurance database between 2008 and 2018 found that only about one third (33.9%) of such … Read more

Study Shows How Ovarian Cancer Starts in High-Risk Women

December 28, 2021 10:47 am

by Cedars-Sinai

Findings Hold Potential for Predicting Many Years in Advance Which Women With the BRCA-1 Mutation Will Develop Disease

Newswise — Los Angeles (December 28, 2021). –Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S., … Read more

Repare Therapeutics’ RP-3500 Shows Potential of ATR Inhibitors in Precision Oncology

November 4, 2021 11:09 am

by Alison Kanski

NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.

Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more

Women with genetic mutations fare no worse with breast or ovarian cancer, study finds

October 1, 2021 12:00 am

By Krista Conger

Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.

Women newly diagnosed with breast or ovarian cancer who are also … Read more

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumor cells

August 13, 2021 9:27 pm

A team of Massachusetts General Hospital (MGH) researchers has discovered how an important class of anti-cancer drugs called PARP inhibitors works, a finding that could help improve treatment and prolong survival for patients with breast cancer and other malignancies.… Read more

Old Antibiotic Targets BRCA-Mutated, PARP Inhibitor-Resistant Tumors

June 18, 2021 12:21 pm

Studies in laboratory cell lines and in mouse tumor models show an antibiotic developed in the 1950s called novabiocin effectively targets and kills cancer cells with abnormal BRCA1 or BRCA2 genes, which normally help to repair damaged DNA.… Read more